Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10370047" target="_blank" >RIV/00216208:11110/17:10370047 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/17:10370047 RIV/00064203:_____/17:10370047 RIV/00064165:_____/17:10370047

Výsledek na webu

<a href="http://dx.doi.org/10.1159/000477962" target="_blank" >http://dx.doi.org/10.1159/000477962</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1159/000477962" target="_blank" >10.1159/000477962</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors

Popis výsledku v původním jazyce

Background: In adults, infliximab (IFX) levels correlate with disease activity, and antibodies to IFX (ATIs) predict treatment failure. We aimed to determine the association of IFX levels and ATIs with disease activity in a paediatric population. We prospectively collected blood, stool, and clinical data from 65 patients (age 10.5-15.1 years) with Crohn&apos;s disease (CD) before IFX administration, and measured IFX trough levels, ATIs, and faecal calprotectin levels (CPT). Samples were collected during maintenance therapy. We used multivariate analysis to identify the predictors of IFX levels. Summary: Lower levels of IFX were associated with ATIs positivity (OR 0.027, 95% CI 0.009-0.077). Higher C-reactive protein (CRP) level, erythrocyte sedimentation rate, and CPT levels were found in patients with lower IFX levels. The optimal combination of sensitivity (0.5) and specificity (0.74) for disease activity was calculated for IFX levels &gt;=1.1 µg/mL using CRP level &lt;5 mg/L as a marker of laboratory remission. In a model that used CPT &lt;=100 µg/g as the definition of remission, the optimal IFX trough level was 3.5 µg/mL. No independent association between remission and ATIs was found in our study population. However, we found an independentz association between IFX levels and serum albumin levels (OR 1.364, 95% CI 1.169-1.593), p &lt; 0.001. Key Messages: The paediatric population was similar to adult populations in terms of the association between IFX and ATIs as well as between IFX and disease activity,

Název v anglickém jazyce

Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors

Popis výsledku anglicky

Background: In adults, infliximab (IFX) levels correlate with disease activity, and antibodies to IFX (ATIs) predict treatment failure. We aimed to determine the association of IFX levels and ATIs with disease activity in a paediatric population. We prospectively collected blood, stool, and clinical data from 65 patients (age 10.5-15.1 years) with Crohn&apos;s disease (CD) before IFX administration, and measured IFX trough levels, ATIs, and faecal calprotectin levels (CPT). Samples were collected during maintenance therapy. We used multivariate analysis to identify the predictors of IFX levels. Summary: Lower levels of IFX were associated with ATIs positivity (OR 0.027, 95% CI 0.009-0.077). Higher C-reactive protein (CRP) level, erythrocyte sedimentation rate, and CPT levels were found in patients with lower IFX levels. The optimal combination of sensitivity (0.5) and specificity (0.74) for disease activity was calculated for IFX levels &gt;=1.1 µg/mL using CRP level &lt;5 mg/L as a marker of laboratory remission. In a model that used CPT &lt;=100 µg/g as the definition of remission, the optimal IFX trough level was 3.5 µg/mL. No independent association between remission and ATIs was found in our study population. However, we found an independentz association between IFX levels and serum albumin levels (OR 1.364, 95% CI 1.169-1.593), p &lt; 0.001. Key Messages: The paediatric population was similar to adult populations in terms of the association between IFX and ATIs as well as between IFX and disease activity,

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30219 - Gastroenterology and hepatology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Digestive Diseases

ISSN

0257-2753

e-ISSN

—

Svazek periodika

36

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

9

Strana od-do

40-48

Kód UT WoS článku

000415245000006

EID výsledku v databázi Scopus

2-s2.0-85027690993